🇺🇸

US SEC Filing Intelligence

· daily

Federal Professional Services Contracts — March 07, 2026

Three engineering services awards totaling $440M obligated (potentials exceeding $2.4B) underscore strong federal demand for NAICS 541330 providers, with USAID favoring small/disadvantaged firms via set-asides. Long-term 5-year contracts to 2028-2030 offer revenue visibility, though varying outlays ($192M total) signal execution pacing risks. Investors should prioritize govcon firms with small biz designations for USAID upside and large players like SAIC for GSA ceilings.

3 total filings
· daily

Significant Contract Modifications ($10M+) — March 07, 2026

This period reveals a $9B surge in significant contract modifications, with ~68% ($6.1B) concentrated in DHS/CBP border barrier/wall projects across Texas sectors, signaling renewed federal infrastructure momentum bullish for specialized construction firms. Healthcare services capture $1.7B (19%) via VA and HHS wins, bolstering UnitedHealth's Optum unit. Remaining $1.2B spans R&D/engineering in space, defense, and humanitarian aid, all under bullish signals with future revenue visibility despite execution risks.

19 total filings
· daily

Contract Option Exercises — March 07, 2026

DHS/CBP dominates with $7.8B+ in border barrier/wall contracts awarded to construction firms like Barnard ($2.6B), Fisher Sand ($1.2B), and Spencer ($954M), signaling massive future revenue from 2026 starts despite $0 outlays to date. UnitedHealth's Optum secures $1.1B in VA healthcare deals, bolstering managed care exposure. Broader themes include firm fixed-price risks in construction and high option upside in services/R&D contracts totaling ~$9B obligated.

19 total filings
· daily

All HHS Contracts — March 07, 2026

SERCO INC's $589M CMS delivery order for eligibility support services, with $442M already outlayed (75% execution), provides high-confidence revenue through June 2026 and potential to 2028 at up to $876M total. This single large HHS contract underscores concentrated spending on health IT infrastructure under NAICS 541512. Investors gain bullish exposure via SERCO but face execution risks from firm-fixed pricing and subawards.

1 total filings
· daily

All DOE Contracts — March 07, 2026

DOE's NNSA awarded General Atomics a $91.4M non-competitive contract for inertial confinement fusion (ICF) targets R&D, with base + options totaling $547.2M through potential 2035, signaling strong revenue visibility for this established player. Total outlays of $43.6M to date and $455.8M in unobligated options highlight front-loaded execution but substantial upside. Investors in nuclear R&D should note sustained federal commitment to experimental sciences amid options exercise risks.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — March 07, 2026

A surge in mega contracts totaling $8.79B highlights a massive ramp-up in DHS/CBP border barrier construction, with 11 awards exceeding $6.5B concentrated in Texas sectors, signaling policy-driven infrastructure acceleration and bullish tailwinds for select contractors. Repeat wins by Barnard Construction ($2.59B across 3 contracts) and Spencer Construction ($954M across 3) underscore execution prowess amid full/open competition. Healthcare services see $1.72B in VA and HHS wins for UnitedHealth/Optum and Serco, while space/defense/USAID add diversified exposure; near-zero outlays ($1.25B total) flag delayed but high-visibility revenue.

17 total filings
· daily

High-Value Federal Grants ($5M+) — March 07, 2026

This period reveals a $9B surge in high-value federal contracts dominated by $6.3B in DHS/CBP border barrier/wall projects across Texas sectors, awarded to a concentrated group of constructors like Barnard ($2.6B across 3 wins) and Spencer ($0.95B across 3 wins). Healthcare services capture $1.7B, led by UnitedHealth's Optum ($1.14B in VA managed care), while R&D/engineering adds $1B with long-tail potential up to $5B+ via options. All 19 awards signal bullish future revenue, though $0 outlays on 14 contracts delay near-term cash flows amid firm-fixed-price execution risks.

19 total filings
· daily

DOE Energy Grants — March 07, 2026

DOE's NNSA non-competitively awarded General Atomics $91.4M for inertial confinement fusion (ICF) targets R&D, with base + options at $547.2M through 2029 and potential to 2035, signaling bullish revenue visibility via cost-plus-fixed-fee structure. $43.6M outlays to date and $1.8M subawards indicate front-loaded progress with low execution risk for this established non-small business. Key upside lies in $455.8M unobligated options amid NNSA's experimental sciences focus.

1 total filings
· daily

General Federal Contracts — March 07, 2026

A surge in DHS/CBP border barrier contracts totaling ~$5.9B across 10 awards signals strong future revenue for construction firms like Barnard (~$2.6B across 3 wins) and Spencer (~$1B across 4 wins), amid zero outlays indicating delayed but committed funding. Healthcare services see $1.1B+ in VA awards to Optum (UnitedHealth sub), while R&D contracts (NASA, DOE, GSA) add diversified upside via unexercised options exceeding $4B potential. All 19 bullish signals prioritize firm fixed price execution risks but highlight sector tailwinds in border security and federal healthcare.

19 total filings
· daily

All NASA Contracts — March 07, 2026

Astrobotic Technology Inc. secured a $314M NASA contract for VIPER rover delivery, with $276M already outlayed, signaling strong execution and committed revenue in space R&D. This full/open competition win by a small business underscores NASA's reliance on commercial providers for lunar missions. Investors should monitor completion risks through October 2026 for potential follow-on opportunities amid firm fixed price exposure.

1 total filings
· daily

Global High-Priority Regulatory Events — March 07, 2026

The 16 filings reveal a dominant theme of financial distress across small-cap Indian companies, with 8 explicit insolvency-related updates (Hindware Home Innovation, Ushdev International, DiGiSPICE Technologies, Reliance Home Finance, Radhagobind Commercial, Tijaria Polypipes, Baron Infotech, JCT Limited) signaling widespread CIRP, liquidation, and creditor meetings amid no disclosed YoY/QoQ financial trends. Neutral-to-negative sentiment prevails (10/16 negative or neutral), with high materiality (avg 7.8/10) driven by NCLT proceedings, contrasting sparse positive regulatory resolutions like MRPL's rumor denial and Rathi's legal clearance. No period-over-period financial comparisons, insider trades (except promoter encumbrance), or capital allocation details are provided, limiting quantitative trends, but forward-looking catalysts cluster around March 2026 (voting results by Mar14, open offer Mar17-Apr2, CoC Mar9, NCLT Mar13). Portfolio-level pattern: Insolvency cluster in manufacturing/niche sectors (pipes, steel, fintech) suggests sector contagion risk, while open offers and mergers offer M&A alpha. Overall, bearish for exposed longs, opportunistic for distress plays.

16 high priority 16 total filings
· daily

Biotech Small-Cap Approvals — March 06, 2026

Four neutral ANDA approvals for generic drugs were granted to small-cap pharma firms (Zydus Pharms, Glenmark Speclt, Epic Pharma LLC, Macleods Pharms Ltd) in early March 2026, signaling standard portfolio expansions without special designations or therapeutic details. This cluster reflects steady FDA throughput for generics but lacks premium positioning or market visibility, muting investment impact. Institutional investors should monitor for launch execution amid pricing risks, viewing this as low-materiality noise in biotech small-caps.

4 total filings
· daily

New Drug Approvals (Original) — March 06, 2026

FDA approved 4 generic ANDAs (all original approvals under standard review) from March 2-4, 2026, enabling portfolio expansions for Zydus Pharms, Glenmark Speclt, Epic Pharma LLC, and Macleods Pharms Ltd. These neutral signals offer incremental revenue potential for generic sponsors amid pricing pressures and unspecified indications/therapeutic areas. No innovative NMEs or special designations limit blockbuster impact, signaling steady but low-materiality generic erosion vs. branded pharma.

4 total filings
· daily

Defense Manufacturing Contracts — March 06, 2026

Science and Engineering Services, LLC (SES), a small minority-owned firm, won an $85M full-and-open CBP aircraft contract, with $57.5M outlayed to date, providing clear revenue visibility through 2027 amid heavy subawarding ($69.5M across 22 subs). Firm-fixed-price structure and long execution timeline introduce material cost overrun risks. This underscores small business capabilities in defense aviation, warranting monitoring for CBP follow-on demand.

1 total filings
· daily

DHS Homeland Security Contracts — March 06, 2026

DHS awarded two large firm fixed price delivery orders totaling $230M, signaling sustained investment in ICE investigative IT ($145M to Palantir) and CBP multi-role enforcement aircraft ($85M to SES), both extending performance to 2027 with 60%+ outlays already booked. Bullish for contractors with revenue visibility, but firm fixed price structures amplify execution risks over multi-year horizons. Cross-cutting theme: DHS prioritizing full/open competition for critical enforcement capabilities amid budget-dependent outlays.

2 total filings
· daily

VA Healthcare & Services Contracts — March 06, 2026

VA awarded $790M in firm fixed price delivery orders for healthcare management (92% to Optum/UnitedHealth Group) and IT services (Deloitte), signaling robust demand and revenue visibility through FY26-28. Both via full/open competition to non-small businesses, with Optum's $724M fully obligated but $0 outlayed vs. Deloitte's $41M already spent. Bullish for healthcare services providers, tempered by execution risks in cost-plus dynamics.

2 total filings
· daily

Federal Construction & Infrastructure Contracts — March 06, 2026

Pernix International, LLC, a small business, secured a $365M firm-fixed-price contract from the Department of State for the Lagos New Consulate Compound, providing multi-year revenue visibility through 2027 but exposing it to full cost overrun risks. This sole large award in federal construction highlights small business competitiveness in infrastructure but flags execution vulnerabilities in a high-value, long-duration project. Investors should monitor outlays and progress for confirmation of bullish momentum.

1 total filings